Fernández-Rodríguez Diego, Bravo María Consuelo, Pizarro Marcela, Vergara-Barra Pablo, Hormazábal María José, Leonario-Rodriguez Marcell
Escuela de Nutrición y Dietética, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago 8580745, Chile.
Academia Científica de Estudiantes de Nutrición y Dietética, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago 8580745, Chile.
Int J Mol Sci. 2025 Aug 21;26(16):8099. doi: 10.3390/ijms26168099.
Probiotics containing spp. have demonstrated immunological and gastrointestinal benefits and may aid in recovery from mood disorders. However, evidence of their mood-modulating efficacy remains inconsistent. Aim: To analyze the efficacy of probiotic interventions with spp. in modulating mood in humans. A scoping review was conducted following the PRISMA guidelines. A systematic search of the PubMed and Scopus databases was performed using nine Boolean combinations of the terms "mental", "mental diseases", "mental disorders", "gastrointestinal microbiome", "gut microbiome", "gut microbiota", and "lactobacillus". The search was limited to clinical trials published in English and limited to ten years of publication. Eligible studies met the following criteria: (a) probiotic interventions in adults, with or without mood disturbances; (b) the use of spp., either alone or in combination; (c) mood assessment instruments applied pre- and post-intervention; and (d) reporting of probiotic concentrations. Trials involving populations with other psychiatric or neurological diagnoses or those combining probiotics with additional mood-modulating nutrients were excluded. From 3291 records, 17 clinical trials met the inclusion criteria. Data extracted included the author, year, population, country of origin, probiotic strain(s), dosage, intervention mode and duration, and outcomes related to the microbial composition, biomarkers, and microbial metabolites. Trials were categorized by probiotic type (single vs. multi-species) and participant profile (healthy individuals and those with depressive symptoms or specific physiological conditions). Preliminary evidence from single-strain interventions, particularly high-dose administered for ≥8 weeks, suggests potential improvements in anxiety, sleep quality, and inflammatory biomarkers. Multi-species formulations yielded reductions in depressive symptoms and changes in neurobiological markers. Nonetheless, substantial heterogeneity in strains, dosages, durations, and outcome measures limited cross-study comparisons. spp. interventions show promising mood-modulating potential, especially with specific strains and prolonged administration. Standardized protocols, rigorous controls, and clearly defined clinical cohorts are needed to establish robust, evidence-based recommendations.
含有 种的益生菌已显示出免疫和胃肠道益处，并可能有助于从情绪障碍中恢复。然而，它们调节情绪功效的证据仍然不一致。目的：分析含有 种的益生菌干预对人类情绪调节的功效。按照PRISMA指南进行了一项范围综述。使用“精神”“精神疾病”“精神障碍”“胃肠道微生物组”“肠道微生物组”“肠道微生物群”和“乳酸杆菌”这几个术语的九种布尔组合，对PubMed和Scopus数据库进行了系统检索。检索仅限于以英文发表的临床试验，且仅限于十年内发表的文献。符合条件的研究满足以下标准：(a) 对有或无情绪障碍的成年人进行益生菌干预；(b) 单独或联合使用 种；(c) 在干预前后应用情绪评估工具；(d) 报告益生菌浓度。涉及有其他精神或神经诊断的人群或那些将益生菌与其他情绪调节营养素联合使用的试验被排除。从3291条记录中，17项临床试验符合纳入标准。提取的数据包括作者、年份、人群、原产国、益生菌菌株、剂量、干预方式和持续时间，以及与微生物组成、生物标志物和微生物代谢物相关的结果。试验按益生菌类型（单菌株与多菌株）和参与者特征（健康个体以及有抑郁症状或特定生理状况的个体）进行分类。单菌株干预的初步证据，特别是≥8周给予高剂量 ，表明焦虑、睡眠质量和炎症生物标志物可能有所改善。多菌株制剂可减轻抑郁症状并改变神经生物学标志物。尽管如此，菌株、剂量、持续时间和结果测量方面的大量异质性限制了跨研究比较。 种干预显示出有前景的情绪调节潜力，特别是特定菌株和长期给药时。需要标准化方案、严格对照和明确界定的临床队列来建立有力的、基于证据的建议。
